Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drospirenone-Ethinyl Estradiol (20µg vs 30µg) in PCOS
NCT07318337Completed
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of drospirenone and ethinyl estradiol in polycystic ovary syndrome (PCOS) (2 arms). Primary endpoint: Free Androgen Index at 12 weeks. Started Jul 2024; status: completed.
02
Drugs
drospirenoneethinyl estradiol
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT07318337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318337.